The United Kingdom's (UK) health secretary, Matt Hancock, on Wednesday said that AstraZeneca had submitted a full data package about its Covid-19 vaccine to the Medicines and Healthcare products Regulatory Agency (MHRA) for approval.
"I'm delighted that the University of Oxford/ AstraZeneca vaccine, developed in the UK, has submitted its full data package to the MHRA for approval. This is the next step towards a decision on the deployment of the coronavirus vaccine," Matt Hancock, UK Health Minister wrote in a tweet.
"Amid all of this difficulty, the great hope for 2021 is of course on the vaccine," he said.
He further stated, "This is the next step towards a decision on the deployment of the vaccine, which is already being manufactured including here in the UK."
We are of course continuing to deploy the Pfizer/BioNTech vaccine, which is being delivered now from over 500 sites all across the UK, and we're adding more all of the time and accelerating the roll-out," Hancock added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)